Innovative Therapeutic Advancements in Heart Health
PHOENIX - Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) continues to lead the way in biotechnology innovations. The company recently received a Notice of Allowance for a critical patent application regarding their ImmCelz™ platform, designed specifically for treating heart failure and addressing post-infarct pathological remodeling.
Understanding the Patent Allowance
The U.S. Patent and Trademark Office (USPTO) has acknowledged the unique therapeutic approach offered by Creative Medical's ImmCelz. The patent, once officially granted, will remain valid until at least 2040, solidifying the company's competitive edge in the regenerative medicine field. This patent encompasses a range of claims aimed at delivering innovative treatments to millions experiencing heart-related conditions.
Addressing Heart Failure
Heart failure is a debilitating condition affecting over five million individuals in the United States alone. It occurs when the heart cannot pump blood effectively, leading to a cascade of health issues. The ImmCelz product addresses both the complications of heart attacks and the subsequent heart remodeling that can compromise functionality. One of the remarkable aspects of this technology is the ultra-minimally invasive outpatient procedure that allows for the re-injection of the patient’s optimized immune cells, offering a promising new avenue for treatment.
Broader Implications for Patient Care
In addition to heart failure, the proposal also highlights the potential benefits for patients struggling with refractory angina—chronic chest pain that remains despite aggressive treatment efforts. With over six million individuals affected by this condition, the ImmCelz product presents a beacon of hope for improved outcomes in cardiac care.
The Vision Behind ImmCelz
CEO Timothy Warbington commented on the significance of this development, stating, "This Notice of Allowance further strengthens our already robust intellectual property portfolio and reflects the potential of our cell-based technology to develop therapies that support the reprogramming, regrowth, and repair of the body across multiple indications.” His vision underscores the transformative impact that these advancements may have on both the company and patient health across various conditions.
A Closer Look at ImmCelz
The ImmCelz platform utilizes patients' own immune cells, which are extracted and then cultivated with optimized cell-free factors, ‘supercharging’ them for reinjection. This innovative technique not only maximizes their inherent healing abilities but also equips them to address multiple health challenges effectively.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is at the forefront of clinical-stage biotechnology focused on regenerative medicine. The company explores various applications, including pain management, neurology, and urology, using cutting-edge cell therapy technologies to craft solutions that truly enhance patient lives.
For more information about their groundbreaking work in regenerative medicine, visit www.creativemedicaltechnology.com.
Frequently Asked Questions
What is the ImmCelz™ platform?
The ImmCelz™ platform is a regenerative medicine solution that uses a patient's immune cells to develop therapies for heart failure and related conditions.
How does the Notice of Allowance impact Creative Medical?
This Notice strengthens their intellectual property portfolio, indicating recognition of the innovation in their therapeutic approach and enhances credibility in the industry.
What conditions will ImmCelz™ target?
The platform is focused on treating heart failure and post-infarct pathological remodeling, among other potential indicators like refractory angina.
Who can benefit from these treatments?
Anyone with heart failure or those vulnerable to cardiovascular issues, including more than five million patients within the U.S., may find relief from the ImmCelz™ therapies.
How long will the patent be effective?
The patent will be in effect until at least 2040, providing a long-term competitive advantage for Creative Medical in the regenerative therapy sector.
